Search Results
Your search for Caroline Helwick ,Caroline Helwick matches 2403 pages
Showing 101 - 150Expert Point of View: Ajay K. Nooka, MD, MPH, and Dan Vogl, MD, MSCE
Ajay K. Nooka, MD, MPH, Professor in the Department of Hematology and Medical Oncology at Emory University, and Dan Vogl, MD, MSCE, Associate Professor of Medicine at the Hospital of the University of Pennsylvania, shared their thoughts on the PERSEUS trial for The ASCO Post. Dr. Nooka noted that ...
Real-World Experience Mirrors PERSEUS Findings
At the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition, researchers from Emory University presented a real-world comparison of the largest cohort of patients with newly diagnosed multiple myeloma consecutively treated with either bortezomib, lenalidomide, and dexamethasone ...
PERSEUS: Daratumumab Regimen Significantly Improves Progression-Free Survival in Newly Diagnosed Multiple Myeloma
The addition of the CD38 monoclonal antibody daratumumab to a standard regimen for patients with newly diagnosed transplant-eligible multiple myeloma significantly prolonged progression-free survival vs standard treatment in the phase III PERSEUS trial. The study was reported as a late-breaking...
Additional Analysis of MATTERHORN Confirms Global Benefit of Durvalumab Plus FLOT in Gastric/Gastroesophageal Junction Cancer
Subgroup analyses of the randomized double-blind phase III MATTERHORN trial continue to show the benefit of adding perioperative durvalumab to standard chemotherapy in patients with locally advanced, resectable gastric or gastroesophageal junction cancer. Detailed findings on pathologic complete...
Long-Term Follow-up of KEYNOTE-590: Benefit of Pembrolizumab Plus Chemotherapy Affirmed in Advanced Esophageal Cancer
Long-term follow-up of the phase III KEYNOTE-590 trial has confirmed the benefit of pembrolizumab plus chemotherapy in advanced esophageal cancer. As compared with chemotherapy alone, after a median follow-up of almost 59 months, patients treated with the chemoimmunotherapy combination were three...
First-Line Nivolumab Plus Ipilimumab Shows Benefit in Metastatic Colorectal Cancer Subset
In the phase III CheckMate 8HW trial, previously untreated patients with microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) metastatic colorectal cancer derived significant benefit from an immunotherapy doublet of nivolumab plus ipilimumab in the first-line setting, which...
Expert Point of View: Rory M. Shallis, MD
Rory M. Shallis, MD, Assistant Professor of Medicine (Hematology) at Yale School of Medicine, shared his thoughts on the use of revumenib in histone-lysine N-methyltransferase 2A-rearranged (KMT2A-rearranged) leukemia, as reported in the phase II AUGMENT-101 trial. In an interview with The ASCO...
AUGMENT-101 Trial: Menin Inhibitor Revumenib Shows Activity in KMT2A-Rearranged Acute Leukemia
In heavily pretreated patients with a challenging type of acute leukemia, the menin inhibitor revumenib demonstrated clinically meaningful activity, including high rates of response and measurable residual disease (MRD) negativity, according to the efficacy and safety results of the phase II...
Antibody-Drug Conjugate Ifinatamab Deruxtecan Shows Robust Activity in Refractory Small Cell Lung Cancer
The antibody-drug conjugate ifinatamab deruxtecan has demonstrated “robust and durable efficacy” in patients with heavily pretreated small cell lung cancer, according to a subset analysis of the DS7300-A-J101 trial presented at the International Association for the Study of Lung Cancer 2023 World...
Expert Point of View: Krishnansu Tewari, MD
Invited discussant Krishnansu Tewari, MD, Associate Professor in the Division of Gynecologic Oncology at the University of California, Irvine, said two new approaches for locally advanced cervical cancer, as described at the European Society for Medical Oncology (ESMO) Congress 2023, represent...
Chemotherapy Induction Before Chemoradiotherapy Improves Survival in Locally Advanced Cervical Cancer
In patients with newly diagnosed, locally advanced cervical cancer, induction chemotherapy prior to chemoradiation therapy led to a 35% reduction in the risk for disease recurrence or death (hazard ratio [HR] = 0.65; P = .013) and a 39% reduction in the survival hazard (HR = 0.61; P = .04),...
Expert Point of View: Bradley J. Monk, MD, FACS, FACOG
Based on the results of the phase III BEATcc trial, there is no longer doubt that immune checkpoint inhibitors have transformed the treatment landscape in cervical cancer—and there is no place for “skeptics” of this approach, according to Bradley J. Monk, MD, FACS, FACOG, Director and Principal...
BEATcc Trial: Atezolizumab-Based Regimen Improves Outcomes in First-Line Setting for Advanced Cervical Cancer
In patients with recurrent or metastatic cervical cancer, the addition of the PD-L1–inhibiting monoclonal antibody atezolizumab to first-line chemotherapy plus the angiogenesis inhibitor bevacizumab significantly improved all efficacy outcomes and yielded a median overall survival that exceeded 2.5 ...
Expert Point of View: Elizabeth Smyth, MD
ASCO discussant Elizabeth Smyth, MD, a consultant medical oncologist at Oxford University Hospitals National Health Service Foundation Trust in the United Kingdom, commented on the EDGE-Gastric trial. This regimen, which evaluated dual checkpoint blockade with next-generation agents, aims to...
Early Data Show Novel Immunotherapy Regimen May Improve Outcomes in Advanced Gastric Cancer
Initial findings from the global phase II EDGE-Gastric trial indicate the potential for two novel immune checkpoint inhibitors to improve outcomes in advanced gastroesophageal adenocarcinoma. The findings were reported at the November 2023 ASCO Plenary Session by Yelena Y. Janjigian, MD, Chief of...
Expert Point of View: S. Vincent Rajkumar, MD
Session moderator S. Vincent Rajkumar, MD, Professor of Medicine at the Mayo Clinic in Rochester, Minnesota, and Chair of the Mayo Clinic Myeloma, Amyloidosis, and Dysproteinemia Group, commented on the GMMG-CONCEPT trial and other studies in newly diagnosed patients. “There are two strategies to...
Sustained MRD Negativity Achieved With Isa-KRd in Newly Diagnosed Multiple Myeloma
For the treatment of newly diagnosed multiple myeloma with high-risk features, a quadruplet regimen of the anti-CD38 antibody isatuximab plus carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) induced high rates of measurable residual disease (MRD) negativity, both in transplant-eligible and...
Understanding the Treatment Options for PD-1–Refractory Melanoma
For the treatment of advanced melanoma that is refractory to anti–PD-1 antibodies, there is no standard approach. The various options, with a look to the future, were discussed by Melinda L. Yushak, MD, MPH, Assistant Professor of Hematology and Oncology at Emory University School of Medicine, at...
Expert Point of View: Sarat Chandarlapaty, MD, PhD
The invited discussant of TROPION-Breast01, Sarat Chandarlapaty, MD, PhD, Member of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center, New York, said the results suggest datopotamab deruxtecan (Dato-DXd) may be a good treatment option for a subset of patients,...
TROPION-Breast01 and DESTINY-Breast04: Antibody-Drug Conjugates of Benefit in Patients With Metastatic Breast Cancer
The TROP-2–directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) significantly improved progression-free survival over standard chemotherapy in the TROPION-Breast01 trial involving patients with previously treated, hormone receptor–positive, HER2-negative, unresectable and/or...
Small Study Identifies Safe, Effective Radiation Dose to Add to Neoadjuvant Chemotherapy and Durvalumab
Low-dose radiotherapy in combination with the monoclonal antibody durvalumab and chemotherapy as neoadjuvant therapy was well tolerated in patients with potentially resectable stage III non–small cell lung cancer (NSCLC), according to a small study conducted in China and presented at the...
Expert Point of View: Faith E. Davies, MD
Since all myelomas are not the same, treatment should be personalized and targeted to the different biological subgroups, said the CANOVA trial’s invited discussant Faith E. Davies, MD, Professor of Medicine, NYU Grossman School of Medicine, New York. For this approach, she said, three things are...
Studies Explore Efficacy of Venetoclax in t(11;14)-Positive Myeloma
In the global randomized phase III CANOVA study, venetoclax plus dexamethasone (VenDex) demonstrated numerically longer progression-free survival compared with pomalidomide and dexamethasone (PomDex) in patients with t(11;14)-positive relapsed or refractory multiple myeloma, though the difference...
Expert Point of View: Solange Peters, MD, PhD and Upal Basu Roy, PhD, MPH
Commenting on the AEGEAN study at the 2023 World Conference on Lung Cancer were the abstract’s invited discussant Solange Peters, MD, PhD, Professor and Chair of Medical Oncology and the Thoracic Malignancies Program at Lausanne University Hospital in Switzerland, and Upal Basu Roy, PhD, MPH,...
Perioperative Durvalumab Improves Surgical Outcomes in Resectable NSCLC: Phase III AEGEAN Trial
The addition of durvalumab to neoadjuvant chemotherapy led to higher rates of R0 resections and posed no apparent impediments to successful surgery for resectable non–small cell lung cancer (NSCLC), according to findings from the randomized phase III AEGEAN trial presented at the International...
Expert Point of View: Krishnansu Tewari, MD
The invited discussant Krishnansu Tewari, MD, Professor in the Division of Gynecologic Oncology at the University of California, Irvine, called innovaTV 301 a “practice-changing study” that should result in full approval of tisotumab vedotin-tftv in the United States “and, importantly, will...
In Recurrent Cervical Cancer, Tisotumab Vedotin-tftv Improves Overall Survival in Phase III Trial
In the global randomized open-label phase III innovaTV 301/ENGOT-cx12/GOG-3057 trial, treatment with the antibody-drug conjugate tisotumab vedotin-tftv resulted in a statistically significant 30% reduction in the risk of death in patients previously treated for recurrent or metastatic cervical...
Expert Point of View: Domenica Lorusso, MD, PhD
Invited discussant of the DUO-E trial, Domenica Lorusso, MD, PhD, commented: “Looking at the data, it’s clear to me that we are entering a new era of clinical research” in endometrial cancer. Patient populations are becoming molecularly refined, which will pave the way for more highly personalized ...
DUO-E Trial: Durvalumab-Based Treatment With or Without Olaparib Boosts Progression-Free Survival in Endometrial Cancer
In the phase III DUO-E trial, a first-line treatment regimen that includes chemotherapy plus the checkpoint inhibitor durvalumab followed by maintenance durvalumab, with or without the PARP inhibitor olaparib, significantly improved progression-free survival in patients with advanced or recurrent...
Expert Point of View: Sarat Chandarlapaty, MD, PhD
The invited discussant of TROPION-Breast01, Sarat Chandarlapaty, MD, PhD, Member of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center, New York, said the results suggest datopotamab deruxtecan (Dato-DXd) may be a good treatment option for a subset of patients,...
TROPION-Breast01 and DESTINY-Breast04: Antibody-Drug Conjugates of Benefit in Patients With Metastatic Breast Cancer
The TROP-2–directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) significantly improved progression-free survival over standard chemotherapy in the TROPION-Breast01 trial involving patients with previously treated, hormone receptor–positive, HER2-negative, unresectable and/or...
Investigational Dual PD-1 and TIGIT Blockade in Advanced Gastroesophageal Cancer
Early findings from the phase II EDGE-Gastric trial indicate the potential for two novel agents to make a difference in advanced gastroesophageal adenocarcinoma, according to findings reported at the ASCO Plenary Series: November 2023 Session by Yelena Y. Janjigian, MD, Chief of the...
Results of PACIFIC Trial Being Replicated in Real-World Settings
Real-world outcomes often fall short of those achieved in clinical trials, but this is apparently not so for patients receiving chemoradiotherapy plus consolidation with durvalumab in unresectable stage III non–small cell lung cancer (NSCLC). The robust results achieved in the phase III PACIFIC...
Expert Point of View: Helena Linardou, MD, PhD
Helena Linardou, MD, PhD, Director of the 4th Department of Oncology and the Comprehensive Clinical Trials Center, Metropolitan Hospital, Athens, was invited as the discussant of the studies on antibody-drug conjugates at the 2023 World Conference on Lung Cancer. Preliminary Data Dr. Linardou...
Role of TROP-2–Directed Antibody-Drug Conjugates With Immune Checkpoint Inhibitors in Advanced NSCLC
Early-phase trials demonstrate the potential for TROP-2–directed antibody-drug conjugates to enhance the response to immune checkpoint inhibitors in patients with advanced non–small cell lung cancer (NSCLC) without actionable genomic alterations, several investigators reported at the International...
Expert Point of View: Helena Linardou, MD, PhD
Helena Linardou, MD, PhD, Director of the 4th Department of Oncology and the Comprehensive Clinical Trials Center, Metropolitan Hospital, Athens, served as discussant of the session on antibody-drug conjugates at the 2023 World Conference on Lung Cancer. Calling antibody-drug conjugates “the next...
HERTHENA-Lung01: Antitumor Activity Shown With HER3-DXd in EGFR-Mutated NSCLC
The treatment of patients with epidermal growth factor receptor (EGFR)-mutated lung cancer that progresses on EGFR-targeted tyrosine kinase inhibitors has been challenging. In the phase II HERTHENA-Lung01 trial, the topoisomerase-1 HER3-targeting antibody-drug conjugate patritumab deruxtecan...
Expert Point of View: Meritxell Bellet Ezquerra, MD, PhD, and Sung-Bae Kim, MD, PhD
The MONARCH 3 study’s invited discussant, Meritxell Bellet Ezquerra, MD, PhD, a senior researcher at the Vall d’Hebron Institute of Oncology in Barcelona, commented: “The second interim analysis for overall survival in MONARCH 31 indicates a positive trend, which was also observed for the subgroup...
Overall Survival in Two Monarch Trials of Abemaciclib in Advanced Breast Cancer
Overall survival results from two trials of abemaciclib in advanced breast cancer were reported at the European Society for Medical Oncology (ESMO) Congress 2022. Both MONARCH 3 and monarcHER previously met their primary endpoints of progression-free survival. The current results for overall...
Expert Point of View: Polly Niravath, MD and Virginia Kaklamani, MD
The invited discussant of the SOFT analysis was Polly Niravath, MD, Associate Professor and Director of the Cancer Survivorship Program at Houston Methodist Hospital in Texas. She noted that the study evaluated the use of the Breast Cancer Index (BCI) as a prognostic tool in early hormone...
SOFT Analysis: Breast Cancer Index May Identify Which Patients Need Ovarian Suppression
In an analysis of the SOFT trial, the Breast Cancer Index accurately identified premenopausal women with hormone receptor–positive early breast cancer who may benefit from ovarian function suppression in addition to adjuvant endocrine therapy. The findings were reported by Ruth O’Regan, MD, Chair...
Expert Point of View: Nancy Chan, MD
Nancy Chan, MD, Director of Breast Cancer Clinical Research at NYU Langone’s Perlmutter Cancer Center, New York, commented on the monarchE analysis for The ASCO Post. She noted that the study investigated the addition of adjuvant abemaciclib (an oral CDK4/6 inhibitor) to endocrine therapy in a...
Update From monarchE: Benefit of Abemaciclib Increases Over Time in Early-Stage Breast Cancer
Results of a planned interim overall survival analysis of the phase III monarchE trial offered further support for the addition of abemaciclib to adjuvant endocrine therapy for patients with hormone receptor–positive, HER2-negative, node-positive, high-risk disease, according to Stephen R.D....
Expert Point of View: Ines Vaz-Luis, MD, PhD
The invited discussant of the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) meta-analysis, Ines Vaz-Luis, MD, PhD, of the Breast Cancer Survivorship Group, Gustave Roussy, Villejuif, France, pointed out that the benefit of ovarian suppression or ablation in reducing breast cancer...
EBCTCG Meta-analysis Confirms Benefit of Ovarian Ablation or Suppression in Preventing Breast Cancer Recurrence
A meta-analysis of randomized trials has revealed a benefit to ovarian ablation or suppression in preventing breast cancer recurrence in premenopausal women with estrogen receptor–positive tumors.1 The findings, based on almost 15,000 women in studies spanning several decades, were presented at the ...
Expert Point of View: Michail Ignatiadis, MD, PhD and Stephen R.D. Johnston, MD, PhD
The September 2023 European Society for Medical Oncology (ESMO) Virtual Plenary presentation of the NATALEE health-related quality-of-life (QOL) findings was discussed by Michail Ignatiadis, MD, PhD, and Stephen R.D. Johnston, MD, PhD. Dr. Ignatiadis is Director of the Breast Medical Oncology...
NATALEE Trial: Quality of Life Maintained for Many Patients Treated With Ribociclib for Early-Stage Breast Cancer
An analysis of patient-reported outcomes in the adjuvant phase III NATALEE trial of ribociclib plus endocrine therapy in early-stage breast cancer showed maintenance of health-related quality of life (QOL), as determined by a number of factors. For patients receiving the inhibitor of...
Expert Point of View: Gentry King, MD
Gentry King, MD, Assistant Professor in the Division of Hematology and Oncology, University of Washington, and Assistant Professor in the Clinical Research Division of Fred Hutchinson Cancer Center, Seattle, offered his thoughts on the findings of NuTide:121. “Only recently, with TOPAZ-1...
NUC-1031/Cisplatin Fails to Improve Outcomes in Advanced Biliary Tract Cancer
As a first-line treatment for advanced biliary tract cancer, an experimental formulation of gemcitabine, NUC-1031, given with cisplatin failed to improve outcomes over standard gemcitabine/cisplatin in the global phase III NuTide:121 trial.1 “NuTide:121 has not advanced the field in biliary tract...
Expert Point of View: Justin F. Gainor, MD
Justin F. Gainor, MD, Director of the Center for Thoracic Cancers Program at Massachusetts General Hospital, Boston, was invited to discuss IMpower151 and ILLUMINATE at the 2023 World Conference on Lung Cancer. IMpower151 vs IMpower150 Dr. Gainor examined why IMpower151 was negative for both...
